VMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of 7.11% compared to Viemed Healthcare's net margin of 12.11%. Viemed Healthcare's return on equity of 9.21% beat Electromed's return on equity of 15.91%.

Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 69.53%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Viemed Healthcare has higher upside potential than Electromed, analysts believe Viemed Healthcare is more attractive than Electromed.

Viemed Healthcare has a beta of 1.504, which suggesting that the stock is 50.437% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $60.7M, which are larger than Electromed quarterly revenues of $16.3M. Viemed Healthcare's net income of $4.3M is higher than Electromed's net income of $2M. Notably, Viemed Healthcare's price-to-earnings ratio is 27.04x while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.38x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 7.11% compared to Viemed Healthcare's net margin of -16.69%. Viemed Healthcare's return on equity of 9.21% beat IRIDEX's return on equity of -157.91%.

Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 69.53%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 76.99%. Given that IRIDEX has higher upside potential than Viemed Healthcare, analysts believe IRIDEX is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.504, which suggesting that the stock is 50.437% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.936, suggesting its less volatile than the S&P 500 by 6.383%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $60.7M, which are larger than IRIDEX quarterly revenues of $11.6M. Viemed Healthcare's net income of $4.3M is higher than IRIDEX's net income of -$1.9M. Notably, Viemed Healthcare's price-to-earnings ratio is 27.04x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.38x versus 0.38x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 7.11% compared to Viemed Healthcare's net margin of -2.16%. Viemed Healthcare's return on equity of 9.21% beat Myomo's return on equity of -48.64%.

Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 69.53%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 70.52%. Given that Myomo has higher upside potential than Viemed Healthcare, analysts believe Myomo is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.504, which suggesting that the stock is 50.437% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $60.7M, which are larger than Myomo quarterly revenues of $12.1M. Viemed Healthcare's net income of $4.3M is higher than Myomo's net income of -$260.1K. Notably, Viemed Healthcare's price-to-earnings ratio is 27.04x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.38x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 7.11% compared to Viemed Healthcare's net margin of -118.53%. Viemed Healthcare's return on equity of 9.21% beat Stereotaxis's return on equity of -139.2%.

Viemed Healthcare has a consensus price target of $12.83, signalling upside risk potential of 69.53%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 145.9%. Given that Stereotaxis has higher upside potential than Viemed Healthcare, analysts believe Stereotaxis is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.504, which suggesting that the stock is 50.437% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $60.7M, which are larger than Stereotaxis quarterly revenues of $6.3M. Viemed Healthcare's net income of $4.3M is higher than Stereotaxis's net income of -$7.5M. Notably, Viemed Healthcare's price-to-earnings ratio is 27.04x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.38x versus 5.79x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.